Life Biosciences Announces Closing of $50 Million Series B Financing Round

BOSTON, Jan. 15, 2019 — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ research and development activities in potential therapeutics to combat age-related decline, and related purposes.

“We are excited by this investor response to our Series B, and the validation it represents,” said Edwards. “The range of investors in this round includes individuals, family trusts, and other professional investors. We believe this response recognizes the power of our teams and science, and the progress we are making in addressing the pathways of aging.”

Life Biosciences Overview
Life Biosciences is dedicated to tackling the eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase healthspans and reduce disease for everyone, including companion animals.

Life Biosciences was co-founded in 2017 by renowned scientists and Tristan Edwards, who developed its innovative structure as Chapter Two in his life after a highly successful career as a global institutional investor working across all asset classes.  There are six Daughter companies working independently and together within the Life Biosciences research environment.

The company also recently announced a significant investment in Prana, a publicly traded Australian biotech company, and the acquisition of Lua, Life Biosciences’ HIPAA-compliant medical technology platform. Life Biosciences provides Daughter companies with the resources required to maximize human potential, including Life Lua’s data and communications platform, experienced management, drug development experience, and a 24,000-square-foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass (USA), in addition to laboratories and offices on four continents.

Co-founded in 2017 by Tristan Edwards and renowned scientists, Life Biosciences is a company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of Life Lua’s data and communications platform; LifeLab, its 24,000- square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

For more information on Life Biosciences, please visit www.lifebiosciences.com.

Press Contact
media@lifebiosciences.com

Life Biosciences Names New Member of Board Of Directors

BOSTON, Dec. 4, 2018 — Life Biosciences Inc. announced today the addition of Logitech’s Bracken Darrell to its board of directors.  Mr. Darrell is chief executive officer at Logitech, where he brings more than 20 years’ experience in business and brand management in successful global consumer companies, including Procter & Gamble, General Electric and Whirlpool. Logitech International S.A. is a Swiss provider of cloud and mobile peripherals, with its headquarters in Lausanne, Switzerland and administrative headquarters in Newark, Ca.

His broad executive management experience has spanned manufacturing, supply chain, product innovation, consumer services and marketing, targeting customers in mature and emerging markets. He has led growth and reinvention for iconic brands such as Old Spice, Braun, and Logitech.

“We could not be more proud and excited to have Bracken join our board,” said Life Biosciences Co-founders David Sinclair, PhD, AO, and Tristan Edwards in a joint statement. “His business and management expertise brings world class consumer insight to our work. As we grow and our work results in new drugs, novel therapies and treatments, Bracken’s respected management and business-building wisdom will be ever more essential.”                              

Life Biosciences was co-founded in 2017 by Dr. Sinclair, a professor in the Department of Genetics at Harvard Medical School, and Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes. In addition to its Daughter company business model, the company invests in other groundbreaking firms, providing them with the resources to maximize their potential.

There are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including the recently acquired Lua’s AI-driven data and communications platform, experienced drug development expertise and its network of laboratories and offices on four continents.

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 24,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company’s Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals. 

For more information on Life Biosciences, please visit www.lifebiosciences.com.         

Press Contact:
susanm@lifebiosciences.com 
erinf@lifebiosciences.com